Shishir K. Maithel, MD, FACS, FSSO ...

Dr. Shishir K. Maithel

Claim this profile

Emory University Hospital/Winship Cancer Institute

Studies Pancreatic Cancer
Studies Pancreatic Calculi
5 reported clinical trials
17 drugs studied

Area of expertise

1Pancreatic Cancer
Shishir K. Maithel has run 2 trials for Pancreatic Cancer. Some of their research focus areas include:
BRCA1 positive
BRCA2 positive
PALB2 positive
2Pancreatic Calculi
Shishir K. Maithel has run 1 trial for Pancreatic Calculi.

Affiliated Hospitals

Image of trial facility.
Emory University Hospital/Winship Cancer Institute
Image of trial facility.
Emory University Hospital Midtown

Clinical Trials Shishir K. Maithel is currently running

Image of trial facility.

Tamsulosin

for Urinary Tract Infections

This study is being done to answer the question: What is the impact of a medication called tamsulosin (also called Flomax) on the rate of postoperative urinary retention (POUR) and catheter-associated urinary tract infection (UTI)? One of the most common complications following surgery and associated with Foley catheters is post-operative urinary retention (POUR) after the catheter is removed. This is defined as being unable to urinate spontaneously within 8 hours following the removal of the indwelling Foley catheter (the catheter that sits in your bladder to drain urine after surgery). When this happens, it requires intermittent straight catheterization of the bladder (placing a temporary catheter in the bladder to drain the buildup of urine), which can cause a lot of discomfort and anxiety, as well as increase the risk of catheter-associated urinary tract infection (CAUTI).
Recruiting2 awards Phase 3
Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria

More about Shishir K. Maithel

Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Shishir K. Maithel has experience with
  • Cefoxitin
  • Piperacillin-tazobactam
  • Cisplatin
  • Gemcitabine Hydrochloride
  • Lymphadenectomy
  • Partial Hepatectomy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Shishir K. Maithel specialize in?
Is Shishir K. Maithel currently recruiting for clinical trials?
Are there any treatments that Shishir K. Maithel has studied deeply?
What is the best way to schedule an appointment with Shishir K. Maithel?
What is the office address of Shishir K. Maithel?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security